What the company does
Aprogen Biologics makes prescription medicines, both conventional small-molecule drugs and biologic medicines (complex drugs derived from living cells), and distributes them to wholesalers, hospitals, clinics, and pharmacies across Korea.
Listed on KOSPI, Korea's main stock exchange, it operates through subsidiaries that handle distribution and, more recently, semiconductor equipment parts. Its pharmaceutical business is divided into a generics segment, producing drugs for cardiovascular, central-nervous-system, digestive, and metabolic conditions, and a biologics segment focused on antibody medicines.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$63.3M
- FY2024US$48.8M
- FY2025US$53.1M
Operating profit
- FY2023−US$41.7M
- FY2024−US$38.3M
- FY2025−US$43.7M
Net income
- FY2023−US$83.6M
- FY2024−US$76.1M
- FY2025−US$122M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
Its biologics manufacturing facility is located in Osong, Chungbuk, and uses a continuous perfusion-culture process to produce antibody drug substances at large scale.
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?